Clinical Trial Update: Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating regorafenib after failure of first-line immune checkpoint inhibitors in advanced hepatocellular carcinoma. The study status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Ju Hyun Shim | Conditions: Carcinoma, Hepatocellular, Hepatic Insufficien | Phase 2 | Status: NOT_YET_RECRUITING